Table 2

Efficacy of TUNA. Non-comparative studies

3 months

6 months

1 year

2 years

3 years

4 years

5 years


Symptom index


Studies

1426,28–30,32,33,35,36,38,43,45–48

1425,26,28–30,32,33,35,36,38,39,41,43,45

1330,32–36,38,39,41,43–45, 47

432,36,43,44

242,44

144

244,49

No. patients

650

661

868

403

297

206

394

Effect

-11.33

-12.52

-12.59

-12.98

-9.94

-10.2

-10.99

95% CI

-14.1,-8.6

-15, -9.9

-14, -11.4

-14.2,- 11.8

-10, -9

-11,-9.

-14,- 8.3

P-value

.000

.000

.000

.000

.000

.000

.000

%improvement

53%

59%

59%

61%

47%

48%

51%


Quality-of-life score


Studies

1226,28,30,32,33,35,36,38,43,45,47,48

1325,26,28,30,32,33,35,36,38,39,41,43,45

1430,32–36,38,39,41,43–47

532,36,43,44,46

144

144

244,49

No. patients

545

646

959

496

206

206

394

Effect

-2.80

-2.79

-2.60

-2.51

-2.1

-1.9

-2.14

95% CI

-3.3, -2.3

-3.2,-2.4

-3, -2.15

-2.8, -2.23

-3.2, -1.

P-value

.000

.000

.000

.000

.000

%improvement

60%

60%

56%

54%

45%

41%

46%


Qmax (mL/s)


Studies

1525,26,28–30,33,35–38,43,45–48

1725,26,28–30,32–39,41,43,45,46

1430,32–36,38,39,41,43–47

432,36,43,44

242,44

144

244,49

No. patients

578

817

960

403

297

206

394

Effect

5.381

5.32

4.40

5.029

3.48

4.10

3.53

95% CI

3.67,7.08

3.7, 6.9

2.94, 5.86

4.35, 5.7

1.5, 5.4

3.2, 4.9

2.9, 4.2

P-value

.000

.000

.000

.000

.001

.000

.000

%improvement

33%

34%

45%

37%

57%

49%

56%


PVR (mL)


Studies

1128,29,33,35–38,43,45,47,48

1028,29,33,35,36,38,39,43,45,46

1033–36,38,39,43,45,47

245,52

NA

NA

149

No. patients

440

557

598

77

188

Effect

-29.55

-37.6

-32.10

-29.5

-58

95% CI

-38.9, -20

-49.7,-25.5

-44,-20

-47.5,- 11.5

-76,-40

P-value

.000

.000

.000

.001

.000

%improvement

28%

36%

31%

28%

56%


Pdet at Qmax (cm H2O)


Studies

332,35,36

726,29,30,32,35–37

232,36

232,36

NA

NA

NA

No. patients

238

247

167

167

Effect

-24.64

-25.36

-22.74

-24.48

95% CI

-35.6,-13.6

-33.2,-17.5

-29.5, -16

-40, -8.92

P-value

.000

.000

.000

.002

%improvement

28%

29%

25%

28%


Prostatic size


Studies

726,28,31,33,35,43,48

529,33,41,43,46

430,33,43,46

143

NA

NA

149

No. patients

242

257

140

8

131

Effect

-6.32

-6.45

-7.89

-7.9

1.9

95% CI

-9.1,-3.5

-9.6,-3.3

-10.6,-5.1

-17.7,1.9

-3.4,7.2

P-value

.00

.00

.00

.11

.48

% reduction

14%

14%

17%

17%

0%


Random effects model. Results are expressed as difference of means and percentage of improvement versus baseline. Abbreviations: CI denotes confidence interval. Qmax denotes maximum urinary flow rate. PVR: Post-void residual volume.‡ impossible to calculate due to lack of data. NA: not available

Bouza et al. BMC Urology 2006 6:14   doi:10.1186/1471-2490-6-14

Open Data